Dr. Janet Chollet

Dr. Janet Chollet has built a career defined by steady engagement in clinical medicine, translational research, and therapeutic development in women’s health. As a board-certified obstetrician–gynecologist and the Co-Founder and Chief Medical Officer of Procyrn LLC, she leads programs centered on sustained-release biologics and reformulated antivirals. Her work focuses on maternal–fetal health, neuroinflammation, and HPV-driven cervical disease, guided by an approach that aims to move scientific concepts toward realistic clinical application.

Over more than three decades, she has contributed to patient care, academic training, and early therapeutic development at major institutions. Her experience includes three U.S. patents in drug-delivery technologies and involvement in several preclinical and early-stage programs. These contributions highlight the value of linking practical clinical insight with methodical research to address unmet medical needs.

Her academic training began with a Bachelor of Science in Neuroscience, followed by a medical degree and a residency in Obstetrics and Gynecology. Those formative clinical years shaped her long-standing interest in improving therapeutic options for women, children, and families. The depth of training provided a strong foundation for her later work in translational medicine, where she sought to align scientific advancement with the realities of clinical practice.

Following residency, she entered academic clinical practice, combining patient care with teaching responsibilities. This period strengthened her understanding of how clinical challenges can inform therapeutic innovation. She later expanded her work through co-founding a women’s health company, where she contributed to drug-delivery systems that led to multiple patents and supported the company’s eventual merger with a public women’s health pharmaceutical organization.

In 2023, she co-founded Procyrn LLC, where she oversees clinical development, regulatory planning, and translational strategy. Her leadership spans programs addressing hypertensive disorders of pregnancy, immune-modulating approaches for ALS, and selective therapeutics for HPV-related cervical dysplasia. She also evaluates exploratory work focused on maternal–fetal immune stabilization and its possible influence on early neurodevelopment. Her approach emphasizes reproducible science, clear decision points, and disciplined planning throughout the development process.

Earlier in her career, she also participated in creative work, co-writing an award-winning episode of a major medical television series. Outside of medicine, she values family, wellness, travel, and creative pursuits, and continues to explore how emerging technologies may support future clinical workflows. Dr. Janet Chollet remains committed to advancing therapies that provide meaningful, measurable benefit to patients while maintaining a strong connection between scientific progress and clinical care.